Agoracom: Small Cap Investment - Resverlogix Corp. - Re: RVX-297 vs RVX-208 for autoimmune indications

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

RVX-297 vs RVX-208 for autoimmune indications

jupiter

Jan 08, 2019 12:18AM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: RVX-297 vs RVX-208 for autoimmune indications

in response to

RVX-297 vs RVX-208 for autoimmune indications

jupiter

posted on Jan 08, 2019 09:12AM

Jupiter,

Great question. This post on that topic may help. Also, read this post on Abbvie's ABBV-744 BD-2 selective BET inhibitor for oncology. Not all BD-2 selective BET inhibitors are create equal. Plus, RVX-297 is entirely pre-clinical. Perhaps RVX-297 is not orally available like RVX-208, which would pose a challenge to clinical development.

BearDownAZ

2 Recommendations